Cardio Diagnostics Holdings, Inc.·Healthcare
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease risk assessment test. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is based in Chicago, Illinois.
Healthcare
Biotechnology
13
2022-01-14
2.66

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics will host an investor conference call on Thursday, February 19, 2026, at 3 p.m. Central Time.

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics will host an investor conference call on Wednesday, February 18, 2026, at 3 p.m. Central Time.

Cardio Diagnostics (NASDAQ: CDIO - Get Free Report) and Allarity Therapeutics (NASDAQ: ALLR - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, risk, profitability and dividends. Volatility and Risk Cardio Diagnostics has a